

Special Issue

COVID-19 Disparities and Vaccine Equity

Message from the Guest Editors

The COVID-19 pandemic has significantly compounded health disparities in several minority populations across the world, further widening gaps in social, political, economic, and racial inequities. Despite the availability of effective vaccines developed against SARS-CoV-2, varying degrees of access and uptake among communities affected by historical and cultural trauma continue to adversely impact minority populations, leading to fractured and ineffective responses to COVID-19 mitigation efforts. This Special Issue intends to explore the dynamics of COVID-19 disparities in minority populations internationally and the impact of mitigation efforts, including vaccines, over the course of the pandemic. Topics of interest may include but are not limited to:

- vaccine hesitancy;
- attitudes and behaviors towards vaccines;
- COVID-19 disparities in infection and mortality disproportionately impacting racial/ethnic groups and/or other minorities;
- community-informed approaches, which may include CBPR methods, communication, and education;
- long-term health impacts of COVID-19.

Guest Editors

Dr. Alikea K. Maunakea

Prof. Dr. Ruben Juarez

Dr. May Okihiro

Deadline for manuscript submissions

closed (31 July 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/125132

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).